Microchip Device for One Hour Antibiotic Resistance Testing
|
By LabMedica International staff writers Posted on 08 Jun 2015 |

Image: Schematic of the antibiotic susceptibility testing device. Bacteria are cultured in miniature chambers, each of which contains a filter for bacterial capture and electrodes for readout of bacterial metabolism (Photo courtesy of the University of Toronto).
A novel electrochemical approach – designed to replace growth or fluorescent tests for drug resistance – can determine within one hour whether a culture of bacteria is susceptible to a particular antibiotic.
At present, the rapid determination of antibiotic susceptibility is hindered by the requirement that, in existing devices, bacteria must be pre-cultured for two to three days to reach detectable levels.
To break this bottleneck, investigators at the University of Toronto (Canada) designed a "lab-on-chip" device containing a series of minute flow-through wells patterned onto a glass chip. Each well has the capacity for only two nanoliters of growth medium and has a filter composed of microbeads at the bottom. The bacterial culture is passed through the well together with the antibiotic being tested, and the organisms are trapped by the filter at the bottom of the well. The bacteria accumulate in the wells, where they remain trapped with the antibiotic and the signal molecule resazurin.
Viable bacteria metabolize resazurin into resorufin, changing its electrochemical signature. If the bacteria are killed by the antibiotic, they stop metabolizing resazurin, and the electrochemical signature of the sample does not change. If they are antibiotic-resistant, they continue to metabolize resazurin into resorufin, altering its electrochemical signature. Electrodes built directly into the chip detect this change,
This electrochemical phenotyping approach was shown to be effective with clinically-relevant levels of bacteria and provided results comparable to culture-based analysis. Results, however, were delivered on a much faster timescale, with resistance profiles available after a single hour of incubation.
"Guessing can lead to resistance to these broad-spectrum antibiotics, and in the case of serious infections, to much worse outcomes for the patient," said first author Justin Besant, a graduate research student at the University of Toronto. "We wanted to determine whether bacteria are susceptible to a particular antibiotic, on a timescale of hours, not days. We have a lot of bacteria in a very small space, so our effective starting concentration is much higher, and as the bacteria multiply and convert the resazurin molecule, it is effectively stuck in this nanoliter droplet—it cannot diffuse away into the solution, so it can accumulate more rapidly to detectable levels."
"The electronics for our electrochemical readout can easily fit in a very small benchtop instrument, and this is something you could see in a doctor's office, for example," said Justin Besant. "The next step would be to create a device that would allow you to test many different antibiotics at many different concentrations, but we are not there yet."
The microchip device for assessing antibiotic resistance was described in the May 13, 2015, online edition of the journal Lab on a Chip.
Related Links:
University of Toronto
At present, the rapid determination of antibiotic susceptibility is hindered by the requirement that, in existing devices, bacteria must be pre-cultured for two to three days to reach detectable levels.
To break this bottleneck, investigators at the University of Toronto (Canada) designed a "lab-on-chip" device containing a series of minute flow-through wells patterned onto a glass chip. Each well has the capacity for only two nanoliters of growth medium and has a filter composed of microbeads at the bottom. The bacterial culture is passed through the well together with the antibiotic being tested, and the organisms are trapped by the filter at the bottom of the well. The bacteria accumulate in the wells, where they remain trapped with the antibiotic and the signal molecule resazurin.
Viable bacteria metabolize resazurin into resorufin, changing its electrochemical signature. If the bacteria are killed by the antibiotic, they stop metabolizing resazurin, and the electrochemical signature of the sample does not change. If they are antibiotic-resistant, they continue to metabolize resazurin into resorufin, altering its electrochemical signature. Electrodes built directly into the chip detect this change,
This electrochemical phenotyping approach was shown to be effective with clinically-relevant levels of bacteria and provided results comparable to culture-based analysis. Results, however, were delivered on a much faster timescale, with resistance profiles available after a single hour of incubation.
"Guessing can lead to resistance to these broad-spectrum antibiotics, and in the case of serious infections, to much worse outcomes for the patient," said first author Justin Besant, a graduate research student at the University of Toronto. "We wanted to determine whether bacteria are susceptible to a particular antibiotic, on a timescale of hours, not days. We have a lot of bacteria in a very small space, so our effective starting concentration is much higher, and as the bacteria multiply and convert the resazurin molecule, it is effectively stuck in this nanoliter droplet—it cannot diffuse away into the solution, so it can accumulate more rapidly to detectable levels."
"The electronics for our electrochemical readout can easily fit in a very small benchtop instrument, and this is something you could see in a doctor's office, for example," said Justin Besant. "The next step would be to create a device that would allow you to test many different antibiotics at many different concentrations, but we are not there yet."
The microchip device for assessing antibiotic resistance was described in the May 13, 2015, online edition of the journal Lab on a Chip.
Related Links:
University of Toronto
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







